News

Amplexa participated in the Workshop NGS Manchester with a talk on "Comparison of NGS Platforms & Software"

More

Amplexa launches two additional Epilepsia NGS panels. One with genes responsible for myoclonic epilepsy and one involved in epilepsia and retardation.

More

As part of our clinical research Amplexa contributes to a presentation on the clinical outcome of having Vitamin D-dependent rickets type 1A due to mutation in CYP27B1 at the ESPE 2013 meeting in Milan, Italy.

More

Amplexa is involved in a study of analysis of SLC2A1 in children with early onset absence epilepsy resulting in the publication "The role of SLC2A1 in early on set and childhood absence epilepsies" in Epilepsy Research.

More

Amplexa and founders decide to expand the development of the firm investing in LIMS systems and accreditation according to ISO standards.

More

Amplexa is invited to lecture at the meeting Medicine and Man, Moscow, with the title "Molecular Genetic Testing in a Clinical Setting" and "Molecular Genetics in Oncology".

More

Amplexa starts providing NGS testing panels for various disorders such as Familial Breast cancer, HNPCC, Osteogenesis Imperfecta and Epilepsia. The list is under constant development based on customer demands.

More